Pulmonary Fibrosis Participation Program: How the PF Registry Connects Patients to Life-Saving Research
In our prior reporting on the evolving landscape of interstitial lung disease, we emphasized that patient registries are the backbone of meaningful clinical advances. The Pulmonary Fibrosis (PF) Registry, a confidential database maintained for individuals diagnosed with PF and their primary supporters, remains a critical tool for accelerating research. As of 2026, the registry has facilitated enrollment in over two dozen interventional trials and observational studies, with the National Jewish Health supplemental oxygen study standing as a landmark investigation into patient quality of life. We continue to urge every PF patient to consider enrolling—your data drives the next generation of therapies.
The PF Registry & National Jewish Health Supplemental Oxygen Study
The PF Registry exists to connect willing participants with researchers who need diverse, real-world cohorts. Investigators at National Jewish Health in Denver, Colorado, are currently enrolling pulmonary fibrosis patients, primary supporters, and physicians from across the United States for a study that examines the impact of supplemental oxygen on functional outcomes. Critically, patients do not need to be currently prescribed oxygen to qualify. This inclusive criterion ensures the study captures a spectrum of disease progression, from early-stage exertional desaturation to advanced hypoxemia. The registry also powers the community forum, where patients exchange ideas for future research and share lived experiences. This participatory model has directly influenced the design of three recent phase 2 trials targeting idiopathic pulmonary fibrosis (IPF).
"The PF Registry is not just a database—it is a partnership between patients and scientists. Every enrollment forms a thread in the fabric of evidence that will define standards of care for decades." — National Jewish Health trial co-investigator (2025).
Source pages: pulmonaryfibrosisresearch.org | Archive reference
Occupational Causes of Pulmonary Fibrosis: Asbestos, Silica, and Drug-Induced Risks
While the PF Registry supports clinical studies, in practical terms, many patients develop pulmonary fibrosis from identifiable external triggers. The most common occupational agents include asbestos fibers, crystalline silica, and coal dust—each capable of triggering a chronic inflammatory response that culminates in lung scarring. Less recognized but equally dangerous are drug-induced causes. The chemotherapy agent bleomycin, the antiarrhythmic amiodarone, and certain immunosuppressants like methotrexate are well-documented inducers of interstitial pneumonitis that can progress to irreversible fibrosis. The FDA has issued multiple adverse event reports linking these medications to pulmonary toxicity. Additionally, radiation therapy for breast or lung cancer frequently causes radiation pneumonitis, which may evolve into fibrotic changes within months.
| Trigger Category | Specific Agent/Exposure | Latency to PF Diagnosis | FDA/CDC Registry |
|---|---|---|---|
| Occupational | Asbestos (chrysotile, crocidolite) | 15–40 years | ATSDR priority list |
| Occupational | Silica (crystalline quartz) | 10–30 years | NIOSH surveillance |
| Drug-Induced | Bleomycin | 1–6 months | FDA adverse event reporting |
| Drug-Induced | Amiodarone | 6–24 months | FDA boxed warning |
| Radiation | Chest radiotherapy (thorax) | 6–18 months | CDC registry for survivors |
The latency periods shown above underscore a critical point: many PF patients were exposed decades before symptoms emerged. This temporal gap complicates both diagnosis and litigation, but it does not extinguish legal rights.
Legal Options & MDL Status for PF Patients
When pulmonary fibrosis stems from occupational or pharmaceutical exposure, affected individuals may be entitled to compensation through mass tort litigation. As of 2026, the primary legal mechanisms include:
- MDL (Multidistrict Litigation): Cases involving asbestos exposure have been consolidated under MDL 875 (Eastern District of Pennsylvania). Drug-induced PF from chemotherapeutic agents may fall under separate MDLs depending on the drug.
- Class action certification is rare in PF claims because individual exposure histories vary widely, but some consumer product cases (e.g., talc litigation) have used class action frameworks for medical monitoring.
- Mass tort filings: Individual plaintiffs can join mass torts against manufacturers of defective drugs or employers responsible for unsafe work environments. Recent settlements involving amiodarone plaintiffs have averaged $300,000–$750,000 per case.
- Statute of limitations restrictions: Most states allow 2–6 years from the date of diagnosis or from when the plaintiff knew (or should have known) the cause. Because PF often presents slowly, many courts apply the “discovery rule” to permit later filing. Missing this window can permanently bar recovery.
- Compensation may cover medical expenses, lost wages, pain and suffering, and in some cases punitive damages if gross negligence is shown.
The FDA continues to monitor adverse event reports for drug-induced pulmonary fibrosis. If you were prescribed a known pulmonary-toxic medication and developed interstitial lung disease, a formal adverse event report should be filed with the FDA MedWatch program. This step strengthens your legal record and helps regulators refine safety warnings.
Every PF patient should understand your legal options. An experienced mass tort attorney can evaluate whether your exposure history—occupational, pharmaceutical, or environmental—supports a claim for damages. Given the complexity of medical causation evidence, early consultation is essential to preserve your rights under the applicable statute of limitations.
Our recommendation: First, enroll in the PF Registry to support research and receive alerts about new trials. Second, gather all exposure history—employment records, prescription timelines, imaging reports—and a pathology-confirmed diagnosis of PF or IPF. Third, contact a law firm with a dedicated mass tort practice for pulmonary conditions. Many firms offer free case review and work on contingency. The intersection of registry participation and legal action is not contradictory; both pathways aim to improve outcomes for the PF community. We remain committed to helping you navigate these options.